Skip to main content
IDWeek 2024 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
Live Streamed
On Demand
On Demand
Back

Session: Beyond the Virus: HIV Therapy and Co-Morbidities Research

154 - Pharmacokinetics and Safety of GS-1720 Following Multiple Ascending Doses in a Phase 1a Study in People Without HIV-1

Thursday, October 17, 2024
1:45 PM – 2:00 PM US PT
Location: 404 AB
Disclosure(s):
Haeyoung Zhang, PharmD, PhD: Gilead Sciences, Inc.: Employee, Stocks/Bonds (Public Company)
Ines Mendes, PharmD: Gilead Sciences, Inc.: Employee, Stocks/Bonds (Public Company)
Eva Mortensen, MD, MS: Gilead Sciences, Inc.: Employee, Stocks/Bonds (Public Company)
Hui Wang, PhD: Gilead Sciences, Inc.: Employee, Stocks/Bonds (Public Company)
Aaron Share, B.Sc: Gilead Sciences, Inc.: Employee, Stocks/Bonds (Public Company)
Monika Sobczyk, M.Sc: Gilead Sciences, Inc.: Employee, Stocks/Bonds (Public Company)
Ramesh Palaparthy, PhD: Gilead Sciences, Inc.: 1475-US-PSP, 1475-WO-PCT, 1474-US-PSP, 1515-US-PSP, 1515-WO-PCT, Employee, Stocks/Bonds (Public Company)
Dhananjay Marathe, PhD: Gilead Sciences, Inc.: Employee, Stocks/Bonds (Public Company)